Last reviewed · How we verify
NCT01040312
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
trial testing CPT-11 in Small Cell Lung Cancer in 321 participants. Completed in 2 September 2015.
29 September 2014
Quick facts
| Lead sponsor | Daiichi Sankyo Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 321 |
| Start date | 15 October 2009 |
| Primary completion | 29 September 2014 |
| Estimated completion | 2 September 2015 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- CPT-11 — full drug profile →
- Platinum analogues — full drug profile →
Conditions studied
- Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Cervical Cancer — all drugs for Cervical Cancer →
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Daiichi Sankyo Co., Ltd. — full company profile →
Who can join
Eligibility, any sex, with Small Cell Lung Cancer or Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine the correlation between UGT1A1 genotypes and the safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for patients with lung cancer, cervical cancer, ovarian cancer and gastric cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01040312
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CPT-11
Trials testing the same drug.
- NCT03387592 — CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas · Phase 2 · terminated
- NCT03303495 — A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC · Phase 3 · unknown
Other recruiting trials for Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
- NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
- NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting
Other Daiichi Sankyo Co., Ltd. trials
Trials by the same sponsor.
- NCT06074705 — A Study of DS-1471a In Subjects With Advanced Solid Tumors · Phase 1 · terminated
- NCT05606094 — Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metasta · completed
- NCT04914520 — Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects · Phase 1 · completed
- NCT04818398 — Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects · Phase 1 · completed
- NCT04821674 — Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01040312 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daiichi Sankyo Co., Ltd.
- Last refreshed: 23 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01040312.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing